Enlivex to Present 3-Month Topline Data from Moderate/Severe Knee Osteoarthritis Trial
ByAinvest
Thursday, Aug 14, 2025 8:31 am ET1min read
ENLV--
The trial, which is a double-blind, randomized, placebo-controlled study, enrolled 134 patients who have completed the 3-month follow-up period. The primary endpoints measure joint pain and function versus placebo at 3, 6, and 12 months post-injection. The trial aims to assess both safety and efficacy of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.
Knee osteoarthritis is a prevalent condition, affecting over 32.5 million Americans and 300 million people worldwide. The first stage of the trial, a Phase I open-label dose-escalation study, was completed to evaluate safety and tolerability and to determine optimal dosing. The ongoing Phase IIa stage is a double-blind, randomized, placebo-controlled trial, assessing both safety and efficacy.
The webinar will provide insights into the potential benefits of Allocetra™ in treating knee osteoarthritis, a condition that significantly impacts the quality of life for millions of people. Investors and stakeholders are encouraged to register for the webinar to gain a deeper understanding of the trial's progress and the potential implications for the company's pipeline.
References:
[1] https://www.stocktitan.net/news/ENLV/enlivex-to-present-3-month-topline-data-from-phase-i-ia-moderate-dstvjf0z0oko.html
Enlivex Therapeutics will host a webinar on August 18 to present 3-month topline results from its Phase IIa trial of Allocetra in patients with moderate to severe knee osteoarthritis. The trial aims to evaluate safety and efficacy of Allocetra, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Osteoarthritis affects over 300 million people worldwide and symptomatic knee osteoarthritis is particularly prevalent.
Enlivex Therapeutics Ltd. (Nasdaq: ENLV) is set to host a webinar on August 18, 2025, at 8:00 AM ET to present 3-month topline results from its Phase IIa trial of Allocetra™ for moderate to severe knee osteoarthritis. The webinar will feature a detailed analysis of the 3-month data from the Phase IIa stage of ENX-CL-05-001, a multi-center, two-stage Phase I/II trial evaluating Allocetra™ in patients with moderate-to-severe knee osteoarthritis.The trial, which is a double-blind, randomized, placebo-controlled study, enrolled 134 patients who have completed the 3-month follow-up period. The primary endpoints measure joint pain and function versus placebo at 3, 6, and 12 months post-injection. The trial aims to assess both safety and efficacy of Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state.
Knee osteoarthritis is a prevalent condition, affecting over 32.5 million Americans and 300 million people worldwide. The first stage of the trial, a Phase I open-label dose-escalation study, was completed to evaluate safety and tolerability and to determine optimal dosing. The ongoing Phase IIa stage is a double-blind, randomized, placebo-controlled trial, assessing both safety and efficacy.
The webinar will provide insights into the potential benefits of Allocetra™ in treating knee osteoarthritis, a condition that significantly impacts the quality of life for millions of people. Investors and stakeholders are encouraged to register for the webinar to gain a deeper understanding of the trial's progress and the potential implications for the company's pipeline.
References:
[1] https://www.stocktitan.net/news/ENLV/enlivex-to-present-3-month-topline-data-from-phase-i-ia-moderate-dstvjf0z0oko.html
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet